Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer.
BACKGROUND
We retrospectively evaluated the efficacy of weekly paclitaxel therapy as second-line treatment for patients with advanced gastric cancer that was refractory to S-1.


METHODS
In total, 33 patients received intravenous paclitaxel (80 mg m(-2)) on days 1, 8 and 15 as part of a 4-week cycle.


RESULTS
Eight patients showed a partial response, 11 showed stable disease and 14 showed disease progression. In total, 171 courses (mean=5.2; range=3-16) were administered. Thirteen cases subsequently underwent third-line treatment. The median survival time and time to progression from the time of second-line treatment was 8.0 months and 4.2 months, respectively. The most common haematological toxicities were leukopenia and neutropenia. Non-haematological toxicities were generally mild to moderate and controllable.


CONCLUSIONS
This study showed favourable therapeutic outcomes for advanced gastric cancer patients. However, it will be necessary to confirm the advantages of paclitaxel treatment for S-1-refractory advanced gastric cancer in a larger population.
Matsuda
Goro
G
Department of Surgery, Gastroenterological Center,Graduate School of Medicine, Yokohama City University, Japan.
Kunisaki
Chikara
C
Makino
Hirochika
H
Fukahori
Michiko
M
Kimura
Jun
J
Sato
Tsutomu
T
Oshima
Takashi
T
Nagano
Yasuhiko
Y
Fuii
Shoichi
S
Takagawa
Ryo
R
Kosaka
Takashi
T
Ono
Hedetaka A
HA
Akiyama
Hirotoshi
H
Ichikawa
Yasushi
Y
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy*
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel